Anzeige
Mehr »
Mittwoch, 22.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H48J | ISIN: SE0009973563 | Ticker-Symbol: 6XP
Stuttgart
22.10.25 | 16:13
2,335 Euro
+2,19 % +0,050
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XSPRAY PHARMA AB Chart 1 Jahr
5-Tage-Chart
XSPRAY PHARMA AB 5-Tage-Chart
RealtimeGeldBriefZeit
2,2602,49022:30

Aktuelle News zur XSPRAY PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08.10.XSpray Pharma AB: Xspray Pharma provides update on the FDA process for Dasynoc - observations at contract manufacturer delay approval131• FDA has issued a Complete Response Letter (CRL) regarding Xspray Pharma's New Drug Application (NDA) for Dasynoc, referring to GMP (Good Manufacturing Practice) observations at a contract manufacturer....
► Artikel lesen
11.09.XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue increased and fully utilized180THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA...
► Artikel lesen
26.08.Listing of subscription rights and paid subscription shares of XSpray Pharma AB286With effect from August 27, 2025, the subscription rights of XSpray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including September 04, 2025. Instrument: Subscription...
► Artikel lesen
25.08.XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue277THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, RUSSIA...
► Artikel lesen
21.08.XFRA CAPITAL ADJUSTMENT INFORMATION - 21.08.2025317Das Instrument 6O1 CA13810W1023 CANTER RESOURCES CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 21.08.2025 und ex Kapitalmassnahme am 22.08.2025 The instrument 6O1 CA13810W1023 CANTER RESOURCES...
► Artikel lesen
XSPRAY PHARMA Aktie jetzt für 0€ handeln
19.08.XSpray Pharma AB: Xspray Pharma Submits XS003 to the FDA - The Company's Second Product Candidate from the HyNap Platform390Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic...
► Artikel lesen
15.08.XSpray Pharma AB: Interim Report Second Quarter 2025155April-June 2025, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -44,885 thousand (-53,620)Earnings per share before dilution amounted to SEK -2.35 (-1.64)Cash flow...
► Artikel lesen
12.08.Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product1
12.08.XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds193Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization...
► Artikel lesen
11.07.XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna155Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate...
► Artikel lesen
27.06.XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc439Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract...
► Artikel lesen
14.05.XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc327The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)...
► Artikel lesen
13.05.XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ)125The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025. Adoption of income statement and balance sheet for the financial...
► Artikel lesen
07.05.XSpray Pharma AB: Interim Report First Quarter 2025177January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•...
► Artikel lesen
08.04.XSpray Pharma AB: Xspray Pharma re-submits its FDA application258Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application...
► Artikel lesen
12.02.XSpray Pharma AB: Interim Report Fourth Quarter 2024130October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow...
► Artikel lesen
20.01.XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025160Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology...
► Artikel lesen
14.11.24Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB384With effect from November 15, 2024, the subscription rights of Xspray Pharma AB will be traded on the list for Equity rights. Trading will continue up until and including November 26, 2024. Instrument:...
► Artikel lesen
12.11.24XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.20242.745Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL...
► Artikel lesen
06.11.24XSpray Pharma AB: Interim Report Third Quarter 2024203July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1